CD38 and Miyoshi myopathy: Daratumumab also interferes in the evaluation of minimal/indetectable residual disease (MRD), since this drug binds to residual MM CD38+ cells, preventing the detection of these cells by anti-CD38 antibodies in conventional flow cytometry (28).